Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-529 in Clostridium-difficile Infection
NCT03065374Phase 2Terminated
- Sponsor
- Immuron Limited
- Start
- Sep 2017
- Primary completion
- Nov 2019
- Modality
- Microbiome Therapeutics, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IMM-529 in Clostridioides difficile infection (CDI), sponsored by Immuron Limited. Started Sep 2017; status: terminated.
02
Drugs
IMM-529
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03065374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065374.